Nautilus Biotechnology is a biotechnology company that is developing a platform for analyzing and understanding the human proteome. The company was founded in 2016 in South San Francisco, California, and is focused on using its technology to improve the diagnosis and treatment of diseases. Nautilus's platform combines advanced proteomics techniques with machine learning algorithms to create a detailed map of the human proteome, which is the set of all proteins in the human body. The company's technology has the potential to enable the development of new drugs and therapies that target specific proteins and pathways involved in disease. Nautilus has raised over $100 million in funding and has partnerships with several leading pharmaceutical companies.